This Simple Test Could Replace the Dreaded Pap Smear
Let's be honest: Pap smears are terrible. Every year, I stare at the ceiling and try my hardest to ignore the scraping of my insides. In the age of AI chatbots and self-driving cars, how has no one figured out a less torturous way to screen for cervical cancer?Well, there is, but chances are you haven't heard about it. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊Back in 2024, the U.S. government approved an HPV self-collection test for the detection of two cancer-causing types of HPV in the cervix. Instead of a pelvic exam, women can gently swab a vaginal sample, which the doctors can use in their cervical cancer screening.Yet despite the FDA approval, most medical offices have been slow in rolling out self-collection tests for patients. That means if you're interested in the Pap smear alternative, you have to personally request it from your doctor. So before you head to your next gyno appointment, learn more about this pain-free alternative to cervical cancer screenings. Related:
There are currently two FDA-approved self-collection tests in the U.S. The first is Onclarity HPV, made by Becton, Dickinson and Company (BD), and Cobas HPV, made by Roche Molecular Systems. Both tests are successful in detecting 14 cancer-causing HPV types, and types 16 and 18.Related:
OB/GYN , works with BD, one of the makers of the two FDA-approved self-collection tests. While it detects for possible cervical cancer like a Pap smear, it does so differently, she tells Parade. A Pap smear takes a spatula and scrapes the cervix for samples. These samples are then placed on a microscope slide and observed for abnormal cells. HPV tests use DNA samples for certain strains. Almost all cervical cancer cases come from long-lasting HPV infection in high-risk strains."The way it's currently reported in labs in the US is you either have high risk or low risk. We don't call out all the different strains of HPV, some of which are more likely to cause cervical cancer than others," Dr. Prabakar explains. "We're not getting into the nitty gritty of what strain a person has, and we're meeting women with a lot of confusion and a lot of questions about the type of HPV they have."
The HPV self-collection test uses a swab about the size of a small tampon. You open the tube and insert the swab into your vagina, where you swirl it around for 20 seconds. Afterward, you close the tube and give it to your doctor, who will send it to the lab for testing.Dr. Prabakar's patients have reported self-collection testing to be easy and pain-free. One appeal is that they can control the depth of the swab insertion, avoiding the usual discomfort you would feel from a pap smear. She says this is an appealing alternative for people who have skipped out on going to the doctor because of the pain of Pap smears, especially if they have a history of trauma.
Related:
Currently, no. Both of the two FDA-approved self-collection tests require vaginal sampling to happen in a health care setting such as a doctor's office, urgent care, pharmacies and mobile clinics. "In my practice, I leave the room and they do it in the bathroom or the exam room. It takes 20 seconds," Dr. Prabakar says.Related:
Research has found self-swabbing is as accurate, if not more, than when a doctor takes a sample. In one study that had each participant swabbed twice, one by themselves and the other by a doctor, higher HPV rates were found in the self-collection samples. A review of the FDA-approved self-swab tests found that the Cobas HPV test by Roche had false negatives in 8.7% of the tested samples. Additionally, there is limited data on how the test works on women who have received the HPV vaccine. The Onclarity HPV test by BD showed differences in detecting the disease between vaccinated and unvaccinated women. The review also found a small risk of false negatives when vaginal creams are present during swabbing. According to the authors, it is unknown how vaginal discharge, tampon use and douching affect the results for both FDA-approved tests.
Dr. Prabakar says there were initial concerns that someone could lie about their sample and swab an unrelated object like a countertop. However, the test has an internal control, usually human β-globin in DNA, where if labs don't detect enough of it, they can tell it is not a good-quality sample."It's foolproof," Dr. Prabakar adds. "Out of all the patients that have done it in my office, I've never had an unsatisfactory one where they had to repeat it."HPV screens are an accepted and validated method of cervical cancer screening. That being said, the only drawback is that it will not completely replace the Pap smear. Dr. Prabakar says if the self-swab comes up positive, people will need to follow up with a Pap smear. "You're not completely eliminating the Pap, but it's pretty close to it," she explains. "For the few who end up having a positive HPV test, then we need to do the Pap to get some cells and see what's going on there."Related:
Most women do not need an annual Pap smear. The guidelines for cervical cancer screenings have shifted for women between 21 and 29 to have Pap smears every three years. Women between 30 and 65 should undergo an HPV test every five years."Screening is not done every year, so it is every three to five years, which a lot of women do not know," says Dr. Prabakar. "We used to send postcards like 'hey, it's time for your annual Pap smear,' but these guidelines have changed."Related:
A major benefit of an HPV self-collection test is that it's covered by insurance. "All of my patients have been able to have it covered, just as they would have with the Pap. It's not been a problem," says Dr. Prabakar. If you do not have insurance, the test is inexpensive, costing less than a hundred dollars.
You may have heard that cervical cancer isn't as deadly as it used to be, and it's true: Thanks to expanded cancer screenings in the mid-1970s, cervical cancer is detected much earlier than it used to be. However, Dr. Prabakar says cervical cancer is still a concerning problem if women avoid getting screened. "A woman dies every 90 seconds from cervical cancer," says Dr. Parbakar. "This is still a prevalent type of cancer throughout the world, and screening does not happen everywhere." Newer alternatives to cervical cancer screenings, like self-collection tests, are what Dr. Parbakar considers a "game-changer" because they're quick and gentle. Additionally, she says that knowing the type of HPV strain a person has may eliminate a lot of invasive procedures. "Cervical cancer is one of those cancers that can be prevented and hopefully eradicated in our lifetime, which is exciting," she concludes.
Up Next:FDA Approves HPV Tests That Allow for Self-Collection in a Health Care Setting. National Cancer Institute.
HPV-Associated Cancers and Precancers. Centers for Disease Control and Prevention.
BD Onclarity™ HPV Assay. BD.
cobas® HPV Test. Roche Diagnostics.
Dr. Cheruba Prabakar, MD, FACOG, is an OB/GYN affiliated with Becton, Dickinson and company (BD).
Evaluation of Pre-Analytical Variables for Human Papillomavirus Primary Screening from Self-Collected Vaginal Swabs. The Journal of Molecular Diagnostics.
Performance of a vaginal self-collection device versus clinician collected cervical samples for the detection of high-risk human papillomavirus. Preventive Medicine Reports.
A review of the FDA-approved molecular testing platforms for human papillomavirus. Journal of the American Society of Cytopathology.
Cervical Cancer: Screening. U.S. Preventive Services Task Force.
Key Statistics for Cervical Cancer. American Cancer Society.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
3 hours ago
- Business Upturn
ProZenith Launches Natural Supplement Formulated for Weight Management Support
By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
4 hours ago
- Yahoo
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
A Nationwide Recall Affecting Thousands of Pounds of Beef Tallow Was Just Issued—Here's What to Know
A Nationwide Recall Affecting Thousands of Pounds of Beef Tallow Was Just Issued—Here's What to Know originally appeared on Parade. Beef tallow becoming the hottest food trend was not on my 2025 bingo card, but here we are. Everywhere you look these days, the byproduct of cooked cow's kidney and loin meat is being touted as a miracle fat worthy of both frying the best French fries you've ever had and slathering on your face as part of a game-changing skincare routine. Restaurants are switching to using it in favor of seed oils, and there are even protein bars chock-full of the stuff, but how did we get here? Can it really hydrate your skin better than Tatcha's The Dewy Skin Cream, and is it really better than using seed oils? 😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔 The jury's still out on both of those claims, but that hasn't stopped influencers and government officials alike from singing its praises as the equivalent of this century's gold rush. Never mind the fact that beef tallow was heavily abandoned during the early 90s due to its high concentration of saturated fat, or the fact that there is no real scientific evidence that suggests that beef tallow has any actual benefits for your skin. Sure, everything is fine in moderation, and you can bet it'll make for some finger-licking good fries, but it probably won't cure your hyperpigmentation, will, however, make you smell like a burger, and if that sounds like a plus, by all means, you do you. Of course, you might second-guess reaching for that giant tub of beef fat when you see that the FDA has issued a nationwide recall on beef tallow and pork lard products due to claims that products distributed across the country were not inspected by the USDA. Sulu Organics, LLC., a distributor in Illinois, issued a recall on 6,166 pounds of its products after several consumer complaints were made to FSIS claiming that the products did not bear the USDA inspection mark. Upon further investigation, FSIS determined that the distributor purchased the products from a regulated facility and repackaged the products into smaller containers that were relabeled without FSIS inspections. Although there have been no reports of illness or adverse reactions, consumers are urged to discard any affected products or return them to the point of purchase for a full refund. You can find the complete list of items affected by the recall here. We think we'll just stick to olive oil.A Nationwide Recall Affecting Thousands of Pounds of Beef Tallow Was Just Issued—Here's What to Know first appeared on Parade on Jun 6, 2025 This story was originally reported by Parade on Jun 6, 2025, where it first appeared.